![](/images/graphics-bg.png)
Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models
Joint Authors
Sugahara, Kunio
Maeda, Yasuhiro
Shimano, Kyoko
Murase, Mikako
Mochiduki, Sachiko
Takemoto, Kana
Kakimoto, Tetsuhiro
Utsumi, Hiroyuki
Oshita, Koichi
Kataoka, Hirotoshi
Source
Journal of Immunology Research
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-23
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Amiselimod (MT-1303) is a novel and selective sphingosine 1-phosphate receptor-1 (S1P1) modulator with a more favorable cardiac safety profile than other S1P1 receptor modulators.
In this study, we evaluated the effects of MT-1303 on the progression of lupus nephritis in two well-known murine systemic lupus erythematosus (SLE) models, MRL/lpr and NZBWF1 mice, compared with those of FK506.
Daily oral doses of 0.1 and 0.3 mg/kg MT-1303 not only inhibited the development of lupus nephritis when administered before onset in MRL/lpr and NZBWF1 mice but also improved symptoms of lupus nephritis when administered after onset in MRL/lpr mice.
Its efficacy in these models was more potent or comparable to that of FK506 (1 and 3 mg/kg).
In histological analysis, treatment with MT-1303 inhibited infiltration of T cells into the kidneys, mesangial expansion, and glomerular sclerosis.
MT-1303 treatment resulted in a marked reduction in T cells and B cells in the peripheral blood and significantly inhibited increases in the number of plasma cells in the spleen and T cells in the kidneys.
In addition, administration of MT-1303 suppressed elevations in serum anti-dsDNA antibody levels in MRL/lpr mice, but not in NZBWF1 mice.
Our findings show that MT-1303 exhibits marked therapeutic effects on lupus nephritis in two SLE models, likely by reducing the infiltration of autoreactive T cells into the kidneys.
These results suggest that MT-1303 has the potential to be used as a therapeutic agent for patients suffering from SLE, including lupus nephritis.
American Psychological Association (APA)
Sugahara, Kunio& Maeda, Yasuhiro& Shimano, Kyoko& Murase, Mikako& Mochiduki, Sachiko& Takemoto, Kana…[et al.]. 2019. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. Journal of Immunology Research،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1176370
Modern Language Association (MLA)
Sugahara, Kunio…[et al.]. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. Journal of Immunology Research No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1176370
American Medical Association (AMA)
Sugahara, Kunio& Maeda, Yasuhiro& Shimano, Kyoko& Murase, Mikako& Mochiduki, Sachiko& Takemoto, Kana…[et al.]. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. Journal of Immunology Research. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1176370
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1176370